However, there is growing evidence that the different isoforms AKT1, AKT2 and AKT3 have non-redundant and partly opposing effects in tumorigenesis, making pan-AKT inhibition in breast cancer inappropriate. This evidence concerns the gene AKT2 and breast carcinoma.